Literature DB >> 25332551

Methotrexate Induced Acute Encephalopathy-Occurrence on Re-challenge and Response to Aminophylline.

Prasanth Ganesan1, Peush Bajpai1, Akash Shah1, Parthasarathy Saikrishnan2, Tenali Gnana Sagar1.   

Abstract

Methotrexate-induced acute encephalopathy is a serious complication of a common chemotherapy agent used in lymphoblastic leukemia. As this drug is considered vital for therapeutic success of leukemia therapy it is often rechallenged in these patients. A patient of acute lymphoblastic leukemia developed mild, transient hemiparesis after the 2nd dose of high dose methotrexate (5 g/m(2)) during the consolidation phase of the BFM-95 protocol. When we repeated the drug in the 3rd cycle he developed severe life threatening quadriparesis and cranial nerve palsies. The toxicity was reversed after treatment with Aminophylline. The relevant literature is reviewed.

Entities:  

Keywords:  Acute lymphoblastic leukemia; Aminophylline; Encephalopathy; Methotrexate

Year:  2013        PMID: 25332551      PMCID: PMC4192154          DOI: 10.1007/s12288-013-0275-y

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  12 in total

1.  Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.

Authors:  D H Mahoney; J J Shuster; R Nitschke; S J Lauer; C P Steuber; N Winick; B Camitta
Journal:  J Clin Oncol       Date:  1998-05       Impact factor: 44.544

2.  Early CNS toxicity after intrathecal methotrexate.

Authors:  Sanju Cyriac; Rejiv Rajendranath; T G Sagar
Journal:  Indian J Hematol Blood Transfus       Date:  2009-01-11       Impact factor: 0.900

3.  Transient cerebral dysfunction secondary to high-dose methotrexate.

Authors:  R W Walker; J C Allen; G Rosen; B Caparros
Journal:  J Clin Oncol       Date:  1986-12       Impact factor: 44.544

Review 4.  Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.

Authors:  I J Cohen; B Stark; C Kaplinsky; R Weitz; S Matz; P Lerman; E Rakowsky; R Vogel; R Zaizov
Journal:  Pediatr Hematol Oncol       Date:  1990       Impact factor: 1.969

5.  Acute methotrexate neurotoxicity: findings on diffusion-weighted imaging and correlation with clinical outcome.

Authors:  Nancy Rollins; Naomi Winick; Robert Bash; Timothy Booth
Journal:  AJNR Am J Neuroradiol       Date:  2004 Nov-Dec       Impact factor: 3.825

Review 6.  Biochemical and clinical aspects of methotrexate neurotoxicity.

Authors:  Sandra Vezmar; Achim Becker; Udo Bode; Ulrich Jaehde
Journal:  Chemotherapy       Date:  2003-05       Impact factor: 2.544

7.  Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia.

Authors:  J E Rubnitz; M V Relling; P L Harrison; J T Sandlund; R C Ribeiro; G K Rivera; S J Thompson; W E Evans; C H Pui
Journal:  Leukemia       Date:  1998-08       Impact factor: 11.528

8.  Patient characteristics associated with high-risk methotrexate concentrations and toxicity.

Authors:  M V Relling; D Fairclough; D Ayers; W R Crom; J H Rodman; C H Pui; W E Evans
Journal:  J Clin Oncol       Date:  1994-08       Impact factor: 44.544

9.  Transient neurologic disturbances induced by high-dose methotrexate treatment.

Authors:  N Jaffe; Y Takaue; T Anzai; R Robertson
Journal:  Cancer       Date:  1985-09-15       Impact factor: 6.860

10.  Aminophylline for methotrexate-induced neurotoxicity.

Authors:  J C Bernini; D W Fort; J C Griener; B J Kane; W B Chappell; B A Kamen
Journal:  Lancet       Date:  1995-03-04       Impact factor: 79.321

View more
  1 in total

1.  Prevalence and management of methotrexate-induced neurotoxicity in pediatric patients with osteosarcoma: a single-center experience.

Authors:  Yair Peled; Dror Levin; Shelly Shiran; Michal Manisterski; Rachel Shukrun; Ronit Elhasid
Journal:  Int J Clin Oncol       Date:  2022-05-31       Impact factor: 3.850

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.